Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while Vanguard S&P 500 Growth Index Fund ETF trades at $87.27 (market cap $27.10B). The key difference: Vanguard S&P 500 Growth Index Fund ETF is far larger — about 2.2× Halozyme Therapeutics Inc. Common Stock's market cap, and Halozyme Therapeutics Inc. Common Stock is more actively traded (2,179,278 versus 1,178,312). Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Vanguard S&P 500 Growth Index Fund ETF for 54 Days on average.
| HALO | VOOG | |
|---|---|---|
Market Cap | $12.58B | $27.10B |
Volume | 2,179,278 | 1,178,312 |
Sector | Health | Broad Market / Factor |
52-Week High | $115.22 | $87.81 |
52-Week Low | $61.63 | $65.32 |
Typical Hold Time | 1 Days | 54 Days |
Enterprise Value | $14.49B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VOOG trades at $87.29, down 0.46% on the day, maintaining a bullish technical stance with strong moving average support. The ETF holds 148 large-cap growth stocks from the S&P 500, with significant technology sector exposure. Recent institutional buying activity from firms like Integrated Wealth Concepts and NewEdge Advisors signals confidence in the growth-focused strategy. Technical indicators show bullish momentum with key support at $85 and resistance at $88.
VOOG's long-term growth potential remains compelling with 400% returns over the past decade and 14% gains year-to-date. The ETF's low 0.07% expense ratio and focus on high-performing growth stocks provide cost-effective exposure to market leaders. However, concentration in technology stocks and sensitivity to interest rate changes present risks. The current neutral oscillator readings suggest potential for consolidation near recent highs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
